• Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials

    12 days ago - By Fierce Biotech

    Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials ntaylor
    Tue, 10/13/2020 - 08:09
    Read more ...

     

  • Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer

    12 days ago - By San Diego Biotechnology

    CARLSBAD, Calif. & LONDON--- $LCTX AMD-Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the w......
    Read more ...

     

  • Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

    12 days ago - By San Diego Biotechnology

    SAN DIEGO--Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, toda......
    Read more ...